Keros Therapeutics (NASDAQ:KROS) Cut to Neutral at Wedbush

Wedbush cut shares of Keros Therapeutics (NASDAQ:KROSFree Report) from an outperform rating to a neutral rating in a research note published on Friday, MarketBeat reports. They currently have $15.00 price target on the stock, down from their prior price target of $47.00.

Other research analysts have also recently issued reports about the stock. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating for the company. Oppenheimer cut their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday. HC Wainwright cut their price target on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a report on Friday, December 13th. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Scotiabank cut their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a report on Thursday. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $52.56.

Get Our Latest Stock Analysis on Keros Therapeutics

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $10.86 on Friday. The firm has a market cap of $439.94 million, a PE ratio of -2.08 and a beta of 1.43. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00. The firm’s fifty day moving average is $36.37 and its two-hundred day moving average is $47.16.

Keros Therapeutics (NASDAQ:KROSGet Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the company posted ($1.33) EPS. The business’s revenue for the quarter was up 4750.0% compared to the same quarter last year. Research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KROS. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the third quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP acquired a new stake in shares of Keros Therapeutics in the third quarter valued at approximately $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

(Get Free Report)

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.

Further Reading

Analyst Recommendations for Keros Therapeutics (NASDAQ:KROS)

Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.